PERLMUTTER ROGER M 4

What Happened

• Roger M. Perlmutter, Chief Executive Officer and Director of Eikon Therapeutics (EIKN), reported conversion of derivative securities on Feb 6, 2026. The Form 4 shows an acquisition of 284,857 common shares via conversion and two dispositions (both labeled as derivative dispositions) totaling 2,124,403 shares (1,268,891 + 855,512). No per-share prices or dollar values are reported (listed as N/A).

Key Details

• Transaction date: 2026-02-06; filing date: 2026-02-10 (filing appears on time under the two-business-day Form 4 rule).
• Prices/values: Not reported (N/A) on the Form 4, so dollar values cannot be determined from this filing.
• Post-transaction holdings: Not specified in the data provided on the filing.
• Footnotes of note:
  • Series A-1 and Series D preferred stock converted into common stock immediately prior to the issuer's IPO on a 1-for-7.4578 basis (Footnotes F1, F2).
  • The securities were held indirectly through Perlmutter Consulting, Inc. for the reporting person’s benefit; he had the sole pecuniary interest (Footnote F3).
• Transaction type on the form: listed as "Conversion of derivative security (C)" with two of the conversion line items marked as dispositions of derivative securities.

Context

• These entries reflect conversions of derivative/preferred securities into common stock around the issuer's IPO, not a straightforward open-market buy or sale. Because prices are not reported, the filing doesn’t show proceeds or economic gain/loss.
• Conversions and derivative "dispositions" can reflect structural corporate events (e.g., conversion of preferred at IPO) rather than an executive signaling intent to buy or sell on the market. The filing is factual and does not indicate the reason for the dispositions.